ARANESP (IN POLYSORBATE) (darbepoetin alfa in polysorbate 80)
ERYTHROPOIESIS-STIMULATING AGENTS·CHEMOTHERAPY-INDUCED ANEMIA·+2
AMGEN
Indication
Chemotherapy-induced anemia
Chemotherapy-induced anemia is a common hematologic complication characterized by a clinically significant reduction in circulating red blood cells and hemoglobin levels in patients undergoing cytotoxic cancer therapy. Read more about Chemotherapy-induced anemia
10 drugs 5 manufacturers
Drugs that treat it
Common Chemotherapy-induced anemia therapies.
Filter & compare in the drug finder →Opens the drug finder with Chemotherapy-induced anemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChemotherapy-induced anemia is a common hematologic complication characterized by a clinically significant reduction in circulating red blood cells and hemoglobin levels in patients undergoing cytotoxic cancer therapy.
The condition primarily impacts the hematopoietic system, arising from chemotherapy-mediated myelosuppression that damages rapidly dividing erythroid progenitor cells in the bone marrow, impairs erythropoiesis, and shortens red blood cell survival.
This cytotoxic impairment is frequently compounded by underlying inflammatory cytokine production, functional or absolute iron deficiency, and blunted endogenous erythropoietin responsiveness.
Clinically, it manifests with impaired tissue oxygen delivery leading to debilitating fatigue, dyspnea, tachycardia, dizziness, and reduced functional capacity, potentially necessitating dose reductions or treatment delays.
- nih.gov
Chemotherapy-induced anemia is a common hematologic complication characterized by a clinically significant reduction in circulating red blood cells and hemoglobin levels in patients undergoing cytotoxic cancer therapy
- dergipark.org.tr
Chemotherapy-induced anemia is a common hematologic complication characterized by a clinically significant reduction in circulating red blood cells and hemoglobin levels in patients undergoing cytotoxic cancer therapy
- dovepress.com
The condition primarily impacts the hematopoietic system, arising from chemotherapy-mediated myelosuppression that damages rapidly dividing erythroid progenitor cells in the bone marrow, impairs erythropoiesis, and shortens red blood cell survival
- healthline.com
The condition primarily impacts the hematopoietic system, arising from chemotherapy-mediated myelosuppression that damages rapidly dividing erythroid progenitor cells in the bone marrow, impairs erythropoiesis, and shortens red blood cell survival Clinically, it manifests with impaired tissue oxygen delivery leading to debilitating fatigue, dyspnea, tachycardia, dizziness, and reduced functional capacity, potentially necessitating dose reductions or treatment delays
- medicalnewstoday.com
The condition primarily impacts the hematopoietic system, arising from chemotherapy-mediated myelosuppression that damages rapidly dividing erythroid progenitor cells in the bone marrow, impairs erythropoiesis, and shortens red blood cell survival
- nih.gov
This cytotoxic impairment is frequently compounded by underlying inflammatory cytokine production, functional or absolute iron deficiency, and blunted endogenous erythropoietin responsiveness
- nih.gov
This cytotoxic impairment is frequently compounded by underlying inflammatory cytokine production, functional or absolute iron deficiency, and blunted endogenous erythropoietin responsiveness
- cancer.gov
Clinically, it manifests with impaired tissue oxygen delivery leading to debilitating fatigue, dyspnea, tachycardia, dizziness, and reduced functional capacity, potentially necessitating dose reductions or treatment delays
- nih.gov
Clinically, it manifests with impaired tissue oxygen delivery leading to debilitating fatigue, dyspnea, tachycardia, dizziness, and reduced functional capacity, potentially necessitating dose reductions or treatment delays
Personalize your experience
Follow Chemotherapy-induced anemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.